Financial Performance - The company reported a significant increase in revenue for the first half of 2024, achieving a total of RMB 500 million, representing a growth of 25% compared to the same period last year[8]. - The company's operating revenue for the reporting period reached ¥1,656,909,962.41, representing a year-on-year increase of 13.53%[13]. - Net profit attributable to shareholders was ¥1,120,906,084.06, up 16.35% compared to the same period last year[13]. - The net profit after deducting non-recurring gains and losses was ¥1,088,820,685.62, reflecting a growth of 16.58% year-on-year[13]. - The company reported a net profit of 1,077,873.45 RMB from its subsidiary Beijing Aimeike Technology Development Co., Ltd.[70]. - The company’s subsidiary Beijing Nobot Biotechnology Co., Ltd. reported a net loss of 12,885,130.77 RMB during the reporting period[70]. - The company reported a total revenue of 1,670,440,351.05 CNY from sales of goods and services in the first half of 2024, compared to 1,419,666,117.50 CNY in the same period of 2023, representing an increase of approximately 17.6%[134]. - The net profit for the first half of 2024 was approximately CNY 1.14 billion, compared to CNY 970 million in the first half of 2023, reflecting an increase of around 17.2%[130]. Market Expansion and Product Development - User data indicates that the active user base has expanded to 1.2 million, marking a 30% increase year-over-year[8]. - New product launches include the "Hi-Body" series, which is expected to contribute an additional RMB 100 million in revenue by the end of 2024[8]. - Market expansion efforts are underway, targeting new regions in Southeast Asia, with an expected market entry by Q4 2024[8]. - The company is investing in R&D for innovative medical beauty technologies, with a budget allocation of RMB 50 million for the upcoming year[8]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[8]. - The company has a rich pipeline of products under development, including a modified hyaluronic acid gel for chin correction and a second-generation facial implant line, with several products in various stages of registration and clinical trials[44]. - The company is focusing on expanding its market share and revenue through diversified product offerings and strategic collaborations[41]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[3]. - The company experienced a significant increase in cash flow from investment activities, totaling ¥1,150,199,968.63, up 17.76% from ¥976,694,129.07 in the previous year[49]. - The company reported a net cash increase of ¥-365,831,511.03, a decline of 134.84% compared to the previous year, primarily due to increased financial product purchases[49]. - The company has a total of 357.25 million RMB in entrusted financial management, with 312.25 million RMB remaining unexpired[67]. - The company has invested RMB 85,565.26 million in acquiring a partial stake in Huons BioPharma Co., Ltd. as part of its fundraising strategy[63]. - The company plans to use up to 1.2 billion RMB of temporarily idle raised funds for cash management, with 1,050 million RMB already allocated to structured deposits[64]. Research and Development - The company completed 33 patent applications and obtained 9 patent authorizations during the reporting period, indicating a strong focus on research and development[21]. - The company is advancing the research project for "Injectable Type A Botulinum Toxin," which has received acceptance for drug registration from the National Medical Products Administration[21]. - The company has undertaken key national R&D projects, contributing to industry standards and enhancing its innovation capabilities[33]. - The company is advancing the injectable deoxycholic acid and hyaluronidase, both in preclinical research stages, with plans to submit clinical trial applications[38]. - The company has completed Phase I clinical trials for the liraglutide injection, targeting chronic weight management for adults with a BMI of 30 kg/m² or higher[37]. Corporate Governance and Compliance - The company emphasizes the importance of maintaining accurate financial reporting and transparency in its operations[2]. - The company has a mature governance structure, holding multiple board meetings and ensuring compliance with legal regulations[91]. - The company has not engaged in any related party transactions during the reporting period, indicating a focus on operational integrity[98]. - The company has not faced any penalties or rectification issues during the reporting period, reflecting good compliance practices[97]. - The company has published its annual corporate social responsibility report for four consecutive years, enhancing its image in the capital market[91]. Environmental and Social Responsibility - The company has implemented an energy management system (ISO5001) and an environmental management system (ISO14001) to enhance energy savings and improve emission controls[90]. - The company is actively working on reducing carbon emissions through various measures, although specific results were not disclosed[89]. - The company has expanded its wastewater treatment capacity from 100 tons per day to 200 tons per day to reduce water pollution[85]. - The company has implemented low-noise equipment and basic noise reduction measures, ensuring compliance with the industrial noise emission standards (GB12348-2008) for Class 3[86]. - The company is conducting voluntary clean production audits to promote energy conservation and emission reduction, with ongoing progress in the audit process[90]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 58,782[111]. - The largest shareholder, Jian Jun, holds 31.10% of the shares, totaling 94,062,420 shares[111]. - The total number of shares held by the top 10 shareholders includes significant increases, with Jian Jun increasing his holdings by 26,874,977 shares during the reporting period[115]. - The company has maintained a "green factory" standard and is actively implementing energy-saving and emission-reduction projects[91]. - The company has committed to not reducing its shareholdings from October 10, 2023, to April 9, 2024, to maintain market stability[93].

| 控股股东、实 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 际控制人及其 | | | | | | | | | | | 附属企业 | 北京诺博特生物科技有限公司 | 全资子公司 | 其他应收款 | 7,800.00 | 500.00 | | 8,300.00 | 借款 | 非经营性往来 | | 上市公司的子 | | | | | | | | | | | | 北京全轩新媒信息技术有限公司 | 全资子公司 | 其他应收款 | 390.00 | 10.00 | | 400.00 | 借款 | 非经营性往来 | | | Imeik（HK）Limited | 全资子公司 | 其他应收款 | 3,862.21 | | | 3,862.21 | 借款 | 非经营性往来 | | | 长沙市爱美客科技有限公司 | 全资子公司 | 其他应收款 | 1,040.00 | | | 1,040.00 | 借款 | 非经营性往来 | | 公司及其附属 | 厦门爱美客投资有限公司 | 全资子公司 | 其他应收款 | | ...

爱美客 20240816_原文 2024 年 08 月 17 日 20:38 发言人 00:00 本次电话会议仅供符合国海证券投资者适当性管理要求的客户以及受邀客户使用。国海证券不会因接收人 收到本次会议相关通知或参加本次会议而视其为客户。本次会议内容不构成任何投资建议。据此做出的任 何投资决策与国海证券、国海证券员工或者关联机构无关。本次会议只是转发国海证券已发布研究报告的 部分观点，仅反映国海证券研究人员于发布完整报告当日的判断，相关内容请以研究所以公开发布报告为 准。 发言人 00:32 会议严禁录音或转发，任何人不得对本次会议的任何内容进行发布、复制、编辑、改编、转载、播放、展 示或以其他任何方式非法使用本次会议的部分或者全部内容，否则将承担相应的法律责任。国海证券就此 保留一切法律权利。在任何情况下，国海证券及其员工对使用本次会议信息或内容所引发的任何直接或间 接损失概不负责。市场有风险投资需谨慎。 发言人 01:05 各位领导，大家晚上好，我是国海商社研究员周玉。今天和大家分享的是医美龙头爱美客的深度报告。继 上次我们做了医美行业的框架性梳理，本次爱美客属于医美产业链中最核心的产品部门当中的这个注 ...

爱美客 20240816_原文 2024 年 08 月 17 日 20:38 发言人 00:00 本次电话会议仅供符合国海证券投资者适当性管理要求的客户以及受邀客户使用。国海证券不会因接收人 收到本次会议相关通知或参加本次会议而视其为客户。本次会议内容不构成任何投资建议。据此做出的任 何投资决策与国海证券、国海证券员工或者关联机构无关。本次会议只是转发国海证券已发布研究报告的 部分观点，仅反映国海证券研究人员于发布完整报告当日的判断，相关内容请以研究所以公开发布报告为 准。 发言人 00:32 会议严禁录音或转发，任何人不得对本次会议的任何内容进行发布、复制、编辑、改编、转载、播放、展 示或以其他任何方式非法使用本次会议的部分或者全部内容，否则将承担相应的法律责任。国海证券就此 保留一切法律权利。在任何情况下，国海证券及其员工对使用本次会议信息或内容所引发的任何直接或间 接损失概不负责。市场有风险投资需谨慎。 发言人 01:05 各位领导，大家晚上好，我是国海商社研究员周玉。今天和大家分享的是医美龙头爱美客的深度报告。继 上次我们做了医美行业的框架性梳理，本次爱美客属于医美产业链中最核心的产品部门当中的这个注 ...

证券代码：300896 证券简称：爱美客 公告编号：2024-025 号 爱美客技术发展股份有限公司 关于被动形成对外提供财务资助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次财务资助的形成系爱美客技术发展股份有限公司（以下简称：公司） 增资下属联营企业艾美创医疗科技（珠海）有限公司（以下简称：艾美创）而形 成，增资后公司对其持股比例由 40%提高至 52%。在增资前艾美创自然人股东罗 清从艾美创借款 200 万元人民币，该行为因本次增资后公司将艾美创纳入合并报 表范围而被动形成对外财务资助。 本次被动提供财务资助的对象为罗清，其系公司新增控股子公司艾美创的少 数股东之一，持有艾美创 26.4%的股权。罗清与上市公司不存在关联关系，其不 是失信被执行人。 三、财务资助协议的主要内容 2、公司对艾美创的增资事项分两期完成，增资金额共 4,000 万元，根据《公 司章程》，该增资事项的审批在董事长审批权限之内，不需要经过董事会审议。 3、根据罗清 2024 年 7 月 23 日向艾美创出具的还款承诺，其已于 2024 年 7 月 ...

-60% -50% -40% -30% -20% -10% 0% 10% 2023/07/04 2023/11/04 2024/03/04 2024/07/04 推荐(首次) 证券分析师 主要数据 | 行业 | 社会服务 | |----------------------------|---------------------------| | 公司网址 | https://www.imeik.net/cn/ | | 大股东 / 持股 | 简军 /31.05% | | 实际控制人 | 简军 | | 总股本 ( 百万股 ) | 302 | | 流通 A 股 ( 百万股 ) | 208 | | 流通 B/H 股 ( 百万股 ) | 0 | | 总市值 ( 亿元 ) | 484 | | 流通 A 股市值 ( 亿元 ) | 334 | | 每股净资产 ( 元 ) | 22.75 | | 资产负债率 (%) | 3.90 | 行情走势图 | | 2022A | 2023A | 2024E | 2025E | 2026E | |---------------------|-----------|-----------|- ...

证券代码：300896 证券简称：爱美客 公告编号：2024-024 号 爱美客技术发展股份有限公司 随着行业的不断发展，公司通过差异化定位，加大研发力度，形成了不同产 品间的优势互补，满足不同层次的客户的需求。注射用 A 型肉毒毒素上市后将与 公司现有医疗器械产品相互协同，提供更完善的医疗美容产品供应，满足日益多 元化的市场需求，提升品牌影响力和核心竞争力。 上述药品上市许可目前正处于审评阶段，后续仍需相关机构进一步核准认证， 审评在各阶段所需的时间和结果均具有一定的不确定性。公司目前尚无法预测其 1 对公司未来业绩的影响，敬请广大投资者注意投资风险。 关于境外生产药品注册上市许可获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱美客技术发展股份有限公司（以下简称"公司"）近日收到国家药品监督 管理局下发的《受理通知书》（受理号：JXSS2400051），获悉公司申请的境外 生产药品注册上市许可已获受理，产品名称为注射用 A 型肉毒毒素，现将相关内 容公告如下： 一、本次上市申请的主要内容 | 申请主体 | 申请事项 | 产品名称 | 受理号 ...

投资评级:增持(维持) 核心观点 | 基本数据 | 2024-07-02 | |------------------------|--------------| | 收盘价 ( 元 ) | 170.55 | | 流通股本 ( 亿股 ) | 2.08 | | 每股净资产 ( 元 ) | 31.81 | | 总股本 ( 亿股 ) | 3.02 | | 最近 12 月市场表现 | | -47% -37% -26% -15% -5% 6% 爱美客 沪深300 分析师 刘洋 SAC 证书编号:S0160521120001 liuyang01@ctsec.com 联系人 李梦萱 limx@ctsec.com 相关报告 1. 《Q1 业绩接近预告上沿,增持彰显 长期信心》 2024-04-25 2. 《 Q1 延续快速增长,多元产品矩阵 驱动长期发展》 2024-04-09 3. 《23 年稳定兑现高增,医美龙头持续 精进》 2024-03-20 事件:独家代理 A 型肉毒毒素 Hutox 国内获受理。爱美客注射用 A 型肉 毒毒素于 6 月 27 日正式获国家药监局注册受理,适应症为中重度眉间纹。该 肉毒为韩国药企 Hu ...

证券研究报告 | 公司动态点评 2024 年 04月 26日 爱美客（300896.SZ） 24Q1 归母净利润增长 27%， 管理费用率显著下降 财务指标 2022A 2023A 2024E 2025E 2026E 增持（维持评级） 营业收入（百万元） 1,939 2,869 3,914 5,130 6,421 股票信息 增长率yoy（%） 33.9 48.0 36.4 31.1 25.2 归母净利润（百万元） 1,264 1,858 2,542 3,317 4,113 行业 医药 增长率yoy（%） 31.9 47.1 36.8 30.5 24.0 2024年4月26日收盘价（元） 297.01 ROE（%） 21.3 28.6 29.7 30.1 28.6 总市值（百万元） 64,261.08 EPS最新摊薄（元） 5.84 8.59 11.75 15.33 19.01 流通市值（百万元） 44,324.63 P/E（倍） 55.4 37.7 27.5 21.1 17.0 总股本（百万股） 216.36 P/B（倍） 12.0 11.0 8.3 6.4 4.9 流通股本（百万股） 149.24 资料来源 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [5]. Core Views - The company reported Q1 2024 revenue of 808 million yuan, a year-on-year increase of 28%, and a net profit attributable to shareholders of 527 million yuan, up 27% year-on-year. The non-recurring net profit attributable to shareholders was 528 million yuan, reflecting a 36.5% year-on-year growth [4]. - The company's strong growth in Q1 2024 is attributed to its product and channel advantages, with a slight decrease in gross margin by 0.7 percentage points due to changes in product structure. Sales expenses increased year-on-year, but the growth in revenue led to a decline in the sales expense ratio. Management expenses decreased by 3.9 percentage points year-on-year, primarily due to last year's listing expenses, while R&D expense ratio saw a slight increase [4]. - The company has established a strong sales team with over 400 personnel covering approximately 7,000 medical beauty institutions across China. It has also enhanced its academic brand through various training and conferences, which helps to strengthen its brand influence in the medical institutions [4]. - Future growth is supported by a rich pipeline of internal R&D and external collaborations, with several projects in different stages of development, including products for aesthetic treatments and partnerships with other companies to expand its product offerings [5]. - The company is expected to benefit from the rising trend of light medical beauty consumption and the increasing brand influence of its products, with projected EPS of 11.24, 14.64, and 18.15 yuan for 2024-2026 [5].